Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CAH Stock Forecast 2026-2027
$219.09
Current Price
$51.56B
Market Cap
Buy 13
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to CAH Price Targets
+25.5%
To High Target of $275.00
+16.4%
To Median Target of $255.00
-8.7%
To Low Target of $200.00
CAH Price Momentum
+0.6%
1 Week Change
-0.8%
1 Month Change
+73.5%
1 Year Change
+6.6%
Year-to-Date Change
-6.2%
From 52W High of $233.60
+81.5%
From 52W Low of $120.72
📊 TOP ANALYST CALLS
Did CAH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cardinal Health is one of their latest high-conviction picks.
Latest CAH Stock Price Targets & Analyst Predictions
Based on our analysis of 24 Wall Street analysts, CAH has a bullish consensus with a median price target of $255.00 (ranging from $200.00 to $275.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $219.09, the median forecast implies a 16.4% upside. This outlook is supported by 13 Buy, 4 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CAH Analyst Ratings
13
Buy
4
Hold
0
Sell
CAH Price Target Range
Low
$200.00
Average
$255.00
High
$275.00
Current: $219.09
Latest CAH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CAH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 24, 2026 | Barclays | Glen Santangelo | Overweight | Maintains | $258.00 |
| Feb 10, 2026 | JP Morgan | Lisa Gill | Neutral | Maintains | $243.00 |
| Feb 10, 2026 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $256.00 |
| Feb 6, 2026 | Mizuho | Steven Valiquette | Outperform | Maintains | $235.00 |
| Jan 29, 2026 | Morgan Stanley | Erin Wright | Overweight | Maintains | $245.00 |
| Jan 15, 2026 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $237.00 |
| Jan 9, 2026 | Citigroup | Daniel Grosslight | Buy | Upgrade | $244.00 |
| Dec 9, 2025 | Barclays | Glen Santangelo | Overweight | Initiates | $243.00 |
| Nov 5, 2025 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $221.00 |
| Nov 4, 2025 | Mizuho | Steven Valiquette | Outperform | Maintains | $210.00 |
| Nov 3, 2025 | TD Cowen | Charles Rhyee | Buy | Maintains | $225.00 |
| Oct 31, 2025 | Citigroup | Daniel Grosslight | Neutral | Maintains | $190.00 |
| Oct 31, 2025 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $220.00 |
| Oct 31, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $220.00 |
| Aug 13, 2025 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $190.00 |
| Aug 13, 2025 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $185.00 |
| Aug 13, 2025 | Baird | Eric Coldwell | Outperform | Maintains | $203.00 |
| Aug 12, 2025 | Leerink Partners | Michael Cherny | Outperform | Maintains | $186.00 |
| Jul 16, 2025 | Morgan Stanley | Erin Wright | Overweight | Maintains | $190.00 |
| Jun 13, 2025 | Citigroup | Daniel Grosslight | Neutral | Maintains | $170.00 |
Cardinal Health Inc. (CAH) Competitors
The following stocks are similar to Cardinal Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CAH
Cardinal Health
mkt cap
51.25B
Cardinal Health Inc. (CAH) Financial Data
Cardinal Health Inc. has a market capitalization of $51.56B with a P/E ratio of 31.2x. The company generates $244.67B in trailing twelve-month revenue with a 0.7% profit margin.
Revenue growth is +18.8% quarter-over-quarter, while maintaining an operating margin of +1.2% and return on equity of -59.3%.
Valuation Metrics
Market Cap
$51.56B
Enterprise Value
$57.51B
P/E Ratio
31.2x
PEG Ratio
1.6x
Price/Sales
0.2x
Growth & Margins
Revenue Growth (YoY)
+18.8%
Gross Margin
+3.7%
Operating Margin
+1.2%
Net Margin
+0.7%
EPS Growth
+16.8%
Financial Health
Cash/Price Ratio
+5.4%
Current Ratio
0.9x
Debt/Equity
-3.3x
ROE
-59.3%
ROA
+3.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cardinal Health Inc. (CAH) Business Model
About Cardinal Health Inc.
What They Do
Provides healthcare services and products.
Business Model
The company operates through two main segments: Pharmaceutical and Specialty Solutions, and Medical. It generates revenue by distributing a wide range of pharmaceutical and medical products to healthcare providers, including hospitals, pharmacies, and surgical centers, while also offering customized solutions to improve supply chain efficiency.
Additional Information
Founded in 1979 and based in Dublin, Ohio, Cardinal Health is one of the top three pharmaceutical wholesalers in the U.S., with a significant presence across North America, Europe, and Asia. The company's diverse operations also include at-home healthcare solutions and logistics services, positioning it as an essential player in the healthcare distribution sector.
Company Information
Sector
Healthcare
Industry
Medical Distribution
Employees
53,084
CEO
Mr. Jason M. Hollar
Country
United States
IPO Year
1987
Website
www.cardinalhealth.comCardinal Health Inc. (CAH) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
ECL gains on strong Q4 results, expanding high-tech water solutions and digital platforms, with Ovivo deal and R&D push supporting growth despite macro headwinds.
Mar 12, 2026
By Zacks Equity Research
Analyst Blog
Can Specialty Momentum Push CAH's Earnings Growth Beyond 25% in FY26?
CAH expects specialty revenues to top $50B in FY26 as its expanding MSO and biopharma services ecosystem helps drive projected EPS growth of 23-26%.
Mar 12, 2026
By Indrajit Bandyopadhyay
Analyst Blog
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI rides strong cardiovascular demand and fast-growing therapeutic devices, but tariffs, OEM weakness and China macro pressures cloud the outlook.
Mar 12, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
CAH anticipates specialty revenues exceeding $50B in FY26, driven by its MSO and biopharma services, with projected EPS growth of 23-26%.
Why It Matters
CAH's projected $50B specialty revenues and strong EPS growth signal robust demand and operational success, likely boosting investor confidence and stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Cardinal Health, Inc. (CAH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
2 days ago
Quick Summary
Cardinal Health, Inc. (CAH) recently presented at the Barclays 28th Annual Global Healthcare Conference, discussing key insights and updates relevant to investors.
Why It Matters
Cardinal Health's participation in a major healthcare conference signals growth opportunities and strategic direction, potentially influencing stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Cardinal Health, Inc. (CAH) Presents at Leerink Global Healthcare Conference 2026 Transcript
4 days ago
Quick Summary
Cardinal Health, Inc. (CAH) presented at the Leerink Global Healthcare Conference 2026, providing insights into their business and future plans.
Why It Matters
Cardinal Health's presentation at a major healthcare conference signals potential insights into its strategy, performance outlook, and market trends, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
The latest jobs report has shown disappointing results, indicating potential challenges in the labor market that may impact economic stability.
Why It Matters
A weak jobs report often signals economic slowdown, potentially leading to lower consumer spending and corporate profits, which can negatively impact stock prices and investor sentiment.
Source: 24/7 Wall Street
Market Sentiment:
Negative
Quick Summary
Cardinal Health (CAH) shares rose 49% over six months, driven by strong pharma distribution, expanded specialty services, and growth in adjacent markets, enhancing earnings outlook.
Why It Matters
CAH's 49% share surge reflects strong performance in pharma distribution and specialty services, indicating robust earnings growth potential that can attract more investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Wall Street analysts' ratings significantly influence investors' decisions on stocks, with changes reported by media impacting stock prices.
Why It Matters
Changes in Wall Street analysts' ratings can significantly influence stock prices, impacting investor decisions and market trends.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About CAH Stock
What is Cardinal Health Inc.'s (CAH) stock forecast for 2026?
Based on our analysis of 24 Wall Street analysts, Cardinal Health Inc. (CAH) has a median price target of $255.00. The highest price target is $275.00 and the lowest is $200.00.
Is CAH stock a good investment in 2026?
According to current analyst ratings, CAH has 13 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $219.09. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CAH stock?
Wall Street analysts predict CAH stock could reach $255.00 in the next 12 months. This represents a 16.4% increase from the current price of $219.09. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cardinal Health Inc.'s business model?
The company operates through two main segments: Pharmaceutical and Specialty Solutions, and Medical. It generates revenue by distributing a wide range of pharmaceutical and medical products to healthcare providers, including hospitals, pharmacies, and surgical centers, while also offering customized solutions to improve supply chain efficiency.
What is the highest forecasted price for CAH Cardinal Health Inc.?
The highest price target for CAH is $275.00 from at , which represents a 25.5% increase from the current price of $219.09.
What is the lowest forecasted price for CAH Cardinal Health Inc.?
The lowest price target for CAH is $200.00 from at , which represents a -8.7% decrease from the current price of $219.09.
What is the overall CAH consensus from analysts for Cardinal Health Inc.?
The overall analyst consensus for CAH is bullish. Out of 24 Wall Street analysts, 13 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $255.00.
How accurate are CAH stock price projections?
Stock price projections, including those for Cardinal Health Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 7:50 AM UTC